Tags

Type your tag names separated by a space and hit enter

The association of anti-parvovirus B19-VP1 unique region antibodies with antiphospholipid antibodies in patients with antiphospholipid syndrome.
Clin Chim Acta. 2010 Aug 05; 411(15-16):1084-9.CC

Abstract

BACKGROUND

Human parvovirus B19 (B19) infection has been identified as a trigger of antiphospholipid syndrome (APS). However, the precise role of B19-VP1 unique region (VP1u) in patients with antiphospholipid syndrome remains unclear.

METHODS

IgM and IgG against B19-VP, and serum levels of antibodies directed against cardiolipin (CL), beta2-glycoprotein-I (beta2GPI) and phospholipid (PhL) were determined using ELISA in 45 APS patients. Humoral responses of anti-B19-VP1u were assessed by Western blot and B19 DNA was detected by nested PCR. Absorption experiments were performed using B19-VP1u protein to determine the binding specificity of antiphospholipid antibodies (aPL).

RESULTS

One and 18 of 45 APS patients had detectable levels of anti-B19-VP IgM and anti-B19-VP IgG, indicating recent and past infection respectively. All serum samples from APS patients with diagnostic pattern DNA(-)/IgM(-)/IgG(+) had anti-B19-VP1u activity. APS patients with anti-B19-VP1u antibody had a 4-fold increased risk for recurrent vascular thrombosis compared with those without anti-B19-VP1u antibody. The binding inhibition of CL, beta2GPI, and PhL by absorption with B19-VP1u ranged from 31.4% to 91.1%, 0.8% to 59.8% and 20.2% to 72.1% respectively. Significantly higher inhibition to beta2GPI by B19-VP1u absorption was observed in APS patients with anti-B19-VP1u antibody than in those without anti-B19-VP1u antibody.

CONCLUSIONS

We show a close association of B19 infection with aPL production and suggest B19-VP1u may be of pathogenetic importance in some patients with APS.

Authors+Show Affiliations

Department of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, ROC.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20385113

Citation

Chen, Der-Yuan, et al. "The Association of Anti-parvovirus B19-VP1 Unique Region Antibodies With Antiphospholipid Antibodies in Patients With Antiphospholipid Syndrome." Clinica Chimica Acta; International Journal of Clinical Chemistry, vol. 411, no. 15-16, 2010, pp. 1084-9.
Chen DY, Tzang BS, Chen YM, et al. The association of anti-parvovirus B19-VP1 unique region antibodies with antiphospholipid antibodies in patients with antiphospholipid syndrome. Clin Chim Acta. 2010;411(15-16):1084-9.
Chen, D. Y., Tzang, B. S., Chen, Y. M., Lan, J. L., Tsai, C. C., & Hsu, T. C. (2010). The association of anti-parvovirus B19-VP1 unique region antibodies with antiphospholipid antibodies in patients with antiphospholipid syndrome. Clinica Chimica Acta; International Journal of Clinical Chemistry, 411(15-16), 1084-9. https://doi.org/10.1016/j.cca.2010.04.004
Chen DY, et al. The Association of Anti-parvovirus B19-VP1 Unique Region Antibodies With Antiphospholipid Antibodies in Patients With Antiphospholipid Syndrome. Clin Chim Acta. 2010 Aug 5;411(15-16):1084-9. PubMed PMID: 20385113.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The association of anti-parvovirus B19-VP1 unique region antibodies with antiphospholipid antibodies in patients with antiphospholipid syndrome. AU - Chen,Der-Yuan, AU - Tzang,Bor-Show, AU - Chen,Yi-Ming, AU - Lan,Joung-Liang, AU - Tsai,Chun-Chou, AU - Hsu,Tsai-Ching, Y1 - 2010/04/10/ PY - 2010/01/31/received PY - 2010/04/02/revised PY - 2010/04/03/accepted PY - 2010/4/14/entrez PY - 2010/4/14/pubmed PY - 2010/9/11/medline SP - 1084 EP - 9 JF - Clinica chimica acta; international journal of clinical chemistry JO - Clin Chim Acta VL - 411 IS - 15-16 N2 - BACKGROUND: Human parvovirus B19 (B19) infection has been identified as a trigger of antiphospholipid syndrome (APS). However, the precise role of B19-VP1 unique region (VP1u) in patients with antiphospholipid syndrome remains unclear. METHODS: IgM and IgG against B19-VP, and serum levels of antibodies directed against cardiolipin (CL), beta2-glycoprotein-I (beta2GPI) and phospholipid (PhL) were determined using ELISA in 45 APS patients. Humoral responses of anti-B19-VP1u were assessed by Western blot and B19 DNA was detected by nested PCR. Absorption experiments were performed using B19-VP1u protein to determine the binding specificity of antiphospholipid antibodies (aPL). RESULTS: One and 18 of 45 APS patients had detectable levels of anti-B19-VP IgM and anti-B19-VP IgG, indicating recent and past infection respectively. All serum samples from APS patients with diagnostic pattern DNA(-)/IgM(-)/IgG(+) had anti-B19-VP1u activity. APS patients with anti-B19-VP1u antibody had a 4-fold increased risk for recurrent vascular thrombosis compared with those without anti-B19-VP1u antibody. The binding inhibition of CL, beta2GPI, and PhL by absorption with B19-VP1u ranged from 31.4% to 91.1%, 0.8% to 59.8% and 20.2% to 72.1% respectively. Significantly higher inhibition to beta2GPI by B19-VP1u absorption was observed in APS patients with anti-B19-VP1u antibody than in those without anti-B19-VP1u antibody. CONCLUSIONS: We show a close association of B19 infection with aPL production and suggest B19-VP1u may be of pathogenetic importance in some patients with APS. SN - 1873-3492 UR - https://www.unboundmedicine.com/medline/citation/20385113/The_association_of_anti_parvovirus_B19_VP1_unique_region_antibodies_with_antiphospholipid_antibodies_in_patients_with_antiphospholipid_syndrome_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0009-8981(10)00260-3 DB - PRIME DP - Unbound Medicine ER -